Recipharm has partnered with market entry firm FHS Unternehmensberatung to target development projects in Austria, Germany and Switzerland.
Sweden-based contract development and manufacturing organisation (CDMO) Recipharm already has a market presence in these German speaking countries - last week it announced it was investing €32m ($43m) in its Munich, Germany lyophilisation plant - but has selected FHS to take further advantage of the region.
“It is not that Recipharm has encountered barriers in these countries,” Torkel Gren, Sales Director for Recipharm Pharmaceutical Development, told Outsourcing-Pharma.com. “We have only decided now to put more resources on the ground in the region to target development projects, which until now has been centred on Scandinavia.
“We believe that there are a lot of opportunities to work with companies in the region at an earlier stage in their product development which is why we have entered into the collaboration now.”
Recipharm already generates about 15% of its turnover from the Munich facility, he said, with this set to increase following last week’s expansion announcement.
“Specifically for the region we will offer complete development services from early formulation all the way to commercial manufacturing.”
Situated in Stuttgart, Germany, FHS was described as “an ideal partner” by Gren due to its experience in the CDMO business and its network within German speaking countries.
“The company is strategically situated close to Stuttgart in Germany near several areas with a lot of Pharma and biotech companies such as Munich, Basel and the Frankfurt area.”
FHS owner, Fritz Speck, said of Recipharm that he was “impressed by the capabilities, the excellent experience and the staff's extraordinary team spirit,” adding clients in the German-speaking market could benefit from the firm’s opportunities.